INTRODUCTION

Dendritic cells (DCs) comprise a network of professional antigen-presenting cells (APC) throughout the body that orchestrate responses to foreign antigens, while keeping in check autoreactive T cells (Steinman et al., 2003a). DCs may initiate (inflammatory DCs) or inhibit (tolerogenic DCs) the antigen-specific response. Apart from preventing pro-inflammatory responses to antigens, tolerance comprises active inhibition of existing effector immune responses against a particular antigen. Depending on the origin of this antigen, we may differentiate tolerance for self-antigens, for antigens that originate in the environment or for alloantigens after transplantation. Breaking tolerance may lead to pathology in all cases: reaction of the adaptive immunity against alloantigen may cause graft rejection; intolerance to foreign antigen predisposes to allergy while immune responses against self-antigen may lead to development of autoimmune disease.

There are different mechanisms by which immune tolerance can be achieved: for instance, removal of pathogenic T cells, inducing, or restoring a balance between pro- and anti-inflammatory immunity or by action of regulatory T cells (Treg). A superior ability of DCs to interact with naïve and experienced T cells and contribute to all mechanisms of immune tolerance makes these attractive candidates for tolerance induction strategies. Tolerogenic DCs prevent the destructive action of self-reactive T cells that had escaped the selection in the thymus, by mechanisms of peripheral tolerance (Steinman et al., 2003a). Stimulation of Th1 and/or Th2-type of the immune response, which sometimes balances the destructive immunity, is also critically dependent on action of DCs (Singh et al., 1999; Kidd, 2003; Amsen et al., 2004). Finally, DCs and Treg are engaged in active dialog and critically depend on each other’s function. Induction and maintenance of Treg depends on DCs while Treg employ their regulatory action through direct interaction with DCs, in addition to affecting effector T cells (Singh et al., 1999; Kidd, 2003; Amsen et al., 2004). Tolerogenetic mechanisms essentially employ the antigen-presenting function of DCs, in which co-stimulatory molecules play an important role. Activation of T cells requires that at least two signals are transferred by the APC: (Steinman et al., 2003a) antigen in the form of peptide bound to MHC molecules (Amsen...
define DCs created confusion since many “new” DC types in tolerogenic capacity. The application of phenotypic labeling to tal conditions, and the differences between strategies to endorse phenotypic volatility of these cells in response to environmen-
difficult, especially because of the high turn-over of DCs, their findings in developmental and functional terms has proven to be result in a wealth of information about the phenotypic het-

The highly increased awareness of the role of DCs in steering the immune system and their possible clinical applications has resulted in a wealth of information about the phenotypic heterogeneity of DCs. However, unequivocal interpretation of these findings in developmental and functional terms has proven to be difficult, especially because of the high turn-over of DCs, their significant mobility between peripheral and immune organs, the phenotypic volatility of these cells in response to environmental conditions, and the differences between strategies to endorse tolerogenic capacity. The application of phenotypic labeling to define DCs created confusion since many “new” DC types in different organs were defined, without a clear view on the possible developmental relationships between these and already known DC types. To illustrate this: in human thymus, three distinct DC populations have been found up to five populations in lymph nodes and tonsils and at least three populations in blood (Lewis and Reizis, 2012). The situation is similarly complex in mice, since up to six different DC types were found in mouse lymph nodes and spleen (Dominguez and Ardavin, 2010).

Understanding the in vivo function of these different DCs and establishing the identity of tolerogenic DCs has consequently taken a while. In general, two schools of thinking have arisen; one that proposes tolerogenicity to be a functional property of DC at a particular (immature) stage in development and another that hypothe-
sizes that a specific tolerogenic DC lineage exists. In favor of the first proposal, immature DC induce anergic T cells, T cells with regulatory properties as well as T cells that secrete immunomodulatory cytokines. However, the immature phenotype of DCs is replaced by mature/inflammatory upon triggering in the periphery by danger/inflammatory signals and migration to the lymph nodes, making the tolerogeneicity of immature DCs a transient phase that can hardly be controlled for therapeutic purposes. Establishment of DCs with a “semi-mature” phenotype, representing cells that have been “matured” in the absence of inflammation, has enabled definition of functional regulatory DCs with a stable phenotype (Lutz and Schuler, 2002). The phenotype of these DCs may vary depending on the “tolerizing” signals they receive but in general, semi-mature DCs are able to present antigens like mature DCs but lack high level pro-inflammatory cytokine production and their repetitive injection prevents autoimmunity in experimental models.

The hypothesis that a specific lineage of DC induces tolerance has been widely accepted as well (Coquerelle and Moser, 2010). Studies demonstrating two types of DCs in the peripheral blood, so called myeloid or conventional (cDCs) and plasmacytoid DCs (pDCs), which had different origins and functions, supported the notion that inflammatory and tolerogenic DCs are unrelated cells with separate precursors. In mice, CD8+ cDCs and tissue-derived cDCs are predominantly immunogenic. Most notably implicated in tolerance induction are CD8+ cDCs (Yamazaki et al., 2008) and pDCs (Nikolic et al., 2009), so these were logical candidates for a special tolerogenic DC lineage in mice. However, CD8+ cDCs are not only tolerogenic but also cross-present antigens and prime CD8 T cells (Crozet et al., 2011). Similarly, the tolerogenic potential of pDCs has been demonstrated in allergic inflammation in vivo (Kool et al., 2009), but pDCs can also stimulate Th1 or Th2 immunity and CD8 T cell responses. This indicates that both CD8+ cDCs and pDCs can perform distinct functions depending on the sum of factors that had influenced their maturation and activa-
tion (Swiacki and Colonna, 2010; Takagi et al., 2011). Together with the identification of a common precursor for cDC and pDC in mice (Auffray et al., 2009), the notion of a separate tolerogenic DC lineage became less plausible.

Since both cDC and pDC as found in blood, bone marrow, or peripheral organs represent the immature stage of the cell, the notion is that “immature” or migratory DCs (plasmacytoid or conventional) are able to down-regulate immunity until they encounter an activation stimulus and become immunostimulatory.
APC. This again strengthens the view that all DC are in principle tolerogenic in steady state, unless triggered by a “danger signal” in the inflammatory context. Therefore, a unifying platform allowing both scenarios under particular conditions would be that by conditioning during differentiation determines the functional plasticity of DCs and their diversity in origin/phenotype has evolved to enable the immune system to “sense” various danger signals with different intensity leading to different functional outcomes depending on the context (Figure 1).

**HARNESSING TOLEROGニック DCs FOR THERAPEUTIC PURPOSES**

Dendritic cells that mediate tolerance induction in vivo exist without doubt. However, it is still debatable whether a particular function demonstrated in vitro may also be exerted in vivo. Immune tolerance can be achieved through different mechanisms and the experimental data from an in vivo system do not discern whether a particular DC subtype employs one or more mechanisms, or what other cells in the system might contribute. For example, thymic DCs have been associated with selection of developing T cells, but a recently established mouse model lacking the majority of DCs (DC-less mice) suggested that DCs are dispensable in thymic negative selection (Yoget al., 2012). Yet, DCs in the periphery remain essential in induction and maintenance of peripheral tolerance, since DC-less mice are able to mount an immune response but fail to regulate it and develop enhanced EAE and progressive myeloproliferative disorders, resulting in spontaneous fatal autoimmunity (Birnberg et al., 2008; Ohnmacht et al., 2009; Yogetal., 2012). The expression of the MOG auto antigen in steady state DCs in the brain induced strong tolerance, correlating with the increased expression of PD-1 on adaptive regulatory T cells (Yoget al., 2012). Taken together, these studies show: (i) that autoimmunity may be activated by other cells than DCs; (ii) that DCs are essential for the maintenance of tolerance; (iii) that DCs may act by enhancing adaptive regulatory T cells.

Human peripheral blood pDCs and a subtype of human blood DCs that expresses CD141 (CD141+ DCs) are believed to mediate tolerance in vivo. Although, there is some phenotypic and functional overlap between human and murine DCs, there are also important differences that prevent straightforward translation of findings between species. For example, while both human and mouse pDCs selectively express TLR7 and TLR9, securing the ability to produce IFN-I in response to TLR7/9 ligation, human pDCs do not produce IL-12p40, which may contribute to their tolerogenic capacities. Both human and murine pDCs express CXCR3 and CXCR4, but human pDCs lack CCR9 expression, which could be related to different maturation state (Drakes et al., 2009). CCR9 is expressed by human CD141+ DCs, which are considered to be a homolog of mouse CD8+ DCs (Jongbloed et al., 2010; Poulin et al., 2010). Yet, human CD141+ DCs do not express the same TLR receptors as the mouse counterpart, thus have different sensor functions (Kaisho, 2012). Skin resident CD141+ DCs are the...
major producer of IL-10, they induce T cell anergy and Tregs that suppress skin inflammation. Interestingly, treatment with vitamin D3 induces skin CD141+ DC-like phenotype on human CD141− DCs (Chu et al., 2012).

Manipulation of mouse DCs in vivo has shown therapeutic potential to control immune response. Selective depletion of mDCs sparing pDCs strongly attenuated autoimmune response and reduced diabetes incidence in NOD mice (Nikolic et al., 2005), and specific selective expansion of pDCs in vivo reduce strong allergic responses (Kool et al., 2009). Depletion of a sub-type of dermal DCs prevents differentiation of effector Th cells and conferred resistance to EAE (King et al., 2010), and elimination of Langerhans cells in the skin decreased the low-dose contact hypersensitivity (Kel et al., 2010). A fine tuning between CD8+ and CD8− cDCs that differentially stimulate Th1 vs. Th2 responses can regulate immunity, but the potential of DCs to stimulate a particular type of helper T cells depends on the type of the stimulatory signal they encounter. Immunoregulatory function of tolerogenic DCs in vivo is usually associated with their incompletely differentiated state. It would be important to learn how to prevent DCs in vivo from acquiring immunizing abilities to avoid lack of control and offer safe therapeutic application in humans.

**IN VITRO GENERATED TOLEROGIC DCs**

Monocytes may be manipulated in vitro to generate DCs with desired function and this has been investigated as immunotherapy to a great extent (Palacka et al., 2003; Figdor et al., 2004; Germain, 2010; Chia et al., 2012; Hong et al., 2012; Palacka and Banchereau, 2012). Development of DCs in vitro under influence of GM-CSF and IL-4, reconstructs the sequence of events established for peripheral tissue DCs although a direct approximation of the in vitro generated DCs to an in vivo existing subset is not possible. Tissue-resident DCs, like immature DCs in culture, are characterized by high endocytic capacity and low surface expression of major histocompatibility complex (MHC) and co-stimulatory molecules. Danger signals or inflammation encountered in the periphery triggers maturation of DCs, enabling these to migrate to the lymph nodes and on their way acquire all necessary tools to initiate an adequate response to phagocytosed antigens. The maturation in vitro is induced by stimulating DCs through pattern-recognition receptors (PRRs), CD40, or by inflammatory cytokines.

Different approaches have been tested to induce tolerogenic DCs in vitro and the features DCs have to fulfill are related to the semi-mature phenotype, resistance to maturation, anti-inflammatory cytokine profiles, and induction of specific T-cell profiles. A tolerogenic state of DCs can be induced using several pharmacological agents such as rapamycin, dexamethasone, Vitamin A, or Vitamin D, cytokines such as IL-10 or different growth factors such as G-CSF, VEGF, VIP, and many others (Rutella et al., 2006). Alternative approach has been tested as well using antisense nucleotides to enforce stable immature phenotype of DCs (Machen et al., 2004). These different tolerogenic DCs may share certain features, such as semi-mature phenotype or the ability to suppress allo-reactive response in the mixed leukocyte reaction (MLR), yet many have specific features not shared by others. An overview of phenotye and functional properties of different ex vivo generated DCs is given in Table 1.

**VITAMIN D AND DEXAMETHASON MODULATED DCs**

The active form of the natural immunomodulator Vitamin D (i.e., 1,25(OH)2D3), alters the behavior of immune cells shifting T lymphocytes into Tregs and modulating differentiation of human peripheral blood monocytes (Piromonti et al., 2000; Griffin et al., 2001; Adorini et al., 2003; Unger et al., 2009; Baek et al., 2011), or mouse bone marrow precursors (Griffin et al., 2001). Interestingly, pDCs do not respond to the modulation by 1,25(OH)2D3 (Penna et al., 2007). Monocyte-derived DCs generated in the presence of 1,25(OH)2D3 (VD3-DC) show a semi-mature phenotype with low MHC-class II expression, low activating co-stimulatory molecules, and production of interleukin IL-10 instead of IL-12 in the culture. In addition, VD3-DCs prevent priming of naïve CD4, or CD8 T cells, induce apoptosis of effector T cells and induce both allo- and auto antigen-specific Tregs from naïve CD4 T cells (van Halteren et al., 2004; Unger et al., 2009; Kleijwegt et al., 2010, 2011, 2013). Similar potential to modulate monocyte development into DCs with tolerogenic phenotype has been shown for dexamethasone (Dex) (Matasic et al., 1999; Piromonti et al., 1999; Rea et al., 2000; Chamorro et al., 2009; Unger et al., 2009). Like VD3-DCs, Dex-DCs possess durable immaturity and a sustained high IL-10 versus low IL-12 production, compared to non-treated monocyte-derived DCs. In mice, application of Dex-DC prior to allograft transplantation significantly prolonged the survival of the grafts in an antigen-dependent fashion. Similar to VD3-DCs, priming with Dex-DC leads to a decrease of IFN-γ-producing cells, while increasing the number of IL-10 producing cells, which could point to the induction of Treg-like Tregs. However, Tregs induced using Dex-DCs suppress in a bystander fashion independent of antigen (Unger et al., 2009). 1,25(OH)2D3 and Dex used in combination generate a third entity of tolerogenic DCs (Combi-DCs), which share most features with VD3-DCs in terms of phenotype and function. Combined treatment with 1,25(OH)2D3 and Dex enhanced the modulation of DCs, compared to either compound alone with respect to surface marker expression, inhibition of pro-inflammatory cytokine production, and attenuation of T cell stimulatory capacity (Ferreira et al., 2012). Most importantly, Combi-DCs retain the capacity instilled by 1,25(OH)2D3 to induce antigen-specific Tregs. In vivo, combined-treated DCs are more potent than IL-10-treated cells to suppress colitis in a murine model (Pedersen et al., 2009).

To further investigate the effects of single vs. combined treatment with 1,25(OH)2D3 or Dex as DC modulators, we performed a 2D-DIGE analysis of protein profiles (Ferreira et al., 2012). At the protein level, 1,25(OH)2D3 induced major changes in proteins involved in iron metabolism, tricarboxylic cycle, and the purine/pyrimidine metabolism/pentose phosphate pathway. Dex alone changed proteins involved in the response to stress in addition to several proteins included in the glycolysis and the MHCII antigen presentation pathway. Combining both compounds resulted in a unique protein profile of Combi-DCs, although with a major impact of the 1,25(OH)2D3. Combi-DCs had a profile closer related to VD3-DCs than to Dex-DCs, which could be due to the experimental setup, since 1,25(OH)2D3
Table 1 | Protocols reported to date that generate tolerogenic DCs from human monocytes.

| Modulator | Treatment start | HLA-DR and co-stimulatory molecules | Inhibitory molecules | Cytokine production | Inhibition of T cells* | Induction of Tregs | Additional characteristics | Reference |
|-----------|----------------|-------------------------------------|----------------------|---------------------|-----------------------|---------------------|--------------------------|-----------|
| IL10      | Monocytes      | HLA-DR low, CD80/86/40 low          | PD-L1, IL-T3, I-lT3, mTNF | Low IL-12           | Yes                   | Yes                 | Strongly polarize Th2 response | Chamorro et al. (2009) |
| Rapamycin | Monocytes      | HLA-DR and CD86 like moDCs          | Not expressed        | Low cytokine production | No                    | No                  | Reduced IFNγ in stimulated cells | Naranjo-Gomez et al. (2011) |
| Aspirine  | Monocytes      | Reduced CD80, CD86, CD40            | ILT3                 | Not reported        | Yes                   | Yes                 | Induce de novo Tregs* | Buckland and Lombardi (2009) |
| Butyric acid | immDCs          | CD80 low; HLA-DR and CD86 like moDCs | Not tested           | Low IL-12, high IL-10 | Yes                   | Not tested          | Strong phagocytic capacity# | Downing et al. (2012) |
| Dexamethasone | Culture day 3 | HLA-DR low, CD80/86/40 low          | Low PD-L1, ILT3      | Low IL-12, high IL-10 | Strong                | Yes                 | Tregs suppress through soluble factors | Unger et al. (2009) |
| Vitamin D3 | Monocytes      | HLA-DR intermediate, CD80/86/40 low | PD-L1, IL-T3, mTNF   | Low IL-12, high IL-10 | Strong                | Yes                 | Migrate to inflammation, confer infectious tolerance | Kleijwegt et al. (2010, 2011) |
| Aspergillus proteases | mm.DC | HLA-DR not tested, CD86 low | ILT4, RALDH-2, NOS, IDO | IL-8, no IL-10, no IL-12 | At a high DC:T ratio | No                  | Induce anergic T cells* | Zimmer et al. (2012) |
| Semen     | Monocytes      | HLA-DR low, CD80/86/40 low          | Not tested           | Low IL-12, TNF, IL-6, high IL-10, TGFβ | Not present | TGFβ-producing | Maturation-resistant phenotype* | Remes et al. (2012) |
| Trophoblast cells | immDC | HLA-DR, CD86 and CD40 high | Not tested           | low IL-12, TNF, high IL-10 | Yes                  | Increase | Migration toward trophoblast cells | Salamone et al. (2012) |
| Oligonucleotides | Monocytes | Inhibited CD80 and CD86 | Unknown               | Unknown              | Unknown              | Unknown             | Increase IL-10 producing B cells | Giannoukakis et al. (2011) |
| Wnt5a     | Monocytes      | HLA-DR, CD80, CD86, CD40 low       | PD-L1, PD-L2 similar to moDC | Low IL-12, high IL-8, IL-10 | Yes                   | IL-10 producing | Wnt5a prevents normal GM-CSF/IL-4 signaling | Valencia et al. (2011) |

*inhibition of proliferation of allogeneic T cells.
*characteristics also demonstrated for VD3-DCs.
treatment started at the beginning of DC differentiation while Dex was added from day 3. Addition of Dex did not seem to interfere with the effects of 1,25(OH)2D3 on protein expression in DCs. The protein interaction networks and pathway analysis demonstrated that combined treatment induces drastic changes in metabolic pathways, which might affect the production of or the response to ROS generation resulting in a Combi-DCs that are less sensitive to death by nutrient starvation and have a robust antioxidative machinery possibly ensuring the survival of Combi-DCs at the inflammation site in autoimmune diseases. Since genetic polymorphisms may influence the response of immune cells to 1,25(OH)2D3 or Dex alone, these findings ensured us that combining the two immunomodulators to overcome potentially insufficient modulation by a single agent is the way to go with respect to clinical translation for immunomodulatory DC therapy.

**MORPHOLOGY AND SURFACE PHENOTYPE OF VD3-TREATED DCs: ACTIVATING VS. INHIBITORY CO-STIMULATORY MOLECULES**

Morphological features of 1,25(OH)2D3 and/or Dex modulated DCs are different from non-treated monocyte-derived - moDCs. Non-modulated moDCs form large clusters of non-adherent cells with small dendrites, Dex-DCs are largely non-adherent but show fewer small dendrites and form smaller clusters than moDCs. In contrast, VD3-DCs and Combi-mDCs are adherent with large spindle-shaped dendrites. Interestingly, this spindle-shaped morphology was prominent when VD3- and Combi-DCs were matured with LPS or CD40-L and less evident when DCs were matured using the inflammatory cytokine cocktail (unpublished observation). DCs treated with 1,25(OH)2D3 and/or Dex maintain CD14 expression and do not express CD1a, although they show high CD11c and DC-SIGN expression confirming that they are DCs with a semi-mature phenotype and not macrophages or arrested at monocyte stage (Unger et al., 2009; Ferreira et al., 2012). Upon maturation, Combi-mDCs maintain high CD14 expression and high phagocytic capacity compared to moDCs, possibly indicating a resistance to maturation. The functional consequences of residual CD14 expression and phagocytosis remain to be investigated.

Modulated DCs show lower expression of MHC-class II and co-stimulatory molecules CD80 and CD86 when compared to moDCs, upon maturation. VD3-DCs express higher levels of PD-L1 and CD86 compared to Dex-DCs and Combi-DCs. However, VD3-DCs and Combi-DCs show a similar ratio of PD-L1/CD86, being higher than that of Dex-DCs. CD86 and PD-L1 belong to the B7 family of receptors, which interact with the members of the CD28 family of molecules (CD28, CTLA-4, ICOS, and PD-1), generating potent activating or inhibitory signals in T lymphocytes. CD28/B7 interactions mediate co-stimulation and phosphorilation, DCs are less reliant on glucose for survival and function, and thus less sensitive to death by nutrient starvation (Steinbrink et al., 1997; Rutella et al., 2006). Proteomics analysis shows that 1,25(OH)2D3 and Dex induce changes in DCs other than IL-10 production alone. Yet, the contribution of IL-10 to the tolerogenic phenotype might be larger than anticipated. TLR-activation induces a metabolic transition in DCs from oxidative phosphorylation to aerobic glycolysis and IL-10 blocks this transition. By switching toward oxidative phosphorylation, DCs are less reliant on glucose for survival and function, and thus less sensitive to death by nutrient starvation (Steinbrink et al., 1997; Rutella et al., 2006; Ferreira et al., 2009). IL-10 is also important for the immunomodulatory effects of VD3-DCs, attenuating Th1 driving forces and being protective in settings ofautoimmunity. Together with TGF-β, IL-10 expression is a hallmark of the presence of regulatory T cells. However, IL-10 does not seem to be involved in the actual suppression by Tregs.

Tumor necrosis factor (TNF) is a pleiotropic cytokine most known for pro-inflammatory (Th1) functions in multiple autoimmune diseases (Braun et al., 2002; Feldmann and Maini, 2003). However, a beneficial effect of TNF in autoimmunity is also acknowledged (Robinson et al., 2001; Ramos-Casals et al., 2008; Ko et al., 2009; Tack et al., 2009). This dual role of TNF is seen in other pathologic conditions such as infectious diseases and cancer (Gimenez, 2003; Calzascia et al., 2007). Diverse roles of TNF in the immune response may be partly inferred by two forms of TNF: a membrane-bound TNF (mTNF), which is cleaved from...
the membrane and released as a soluble cytokine (sTNF) (Black et al., 1997). We demonstrated that VD3-DC produce increased amounts of sTNF upon LPS stimulation. Yet, the expression of mTNF distinguishes VD3-DCs from moDCs (Black et al., 1997; Kleijwegt et al., 2010). We further demonstrated that mTNF is essential for the induction of allo-specific suppressive T cells by VD3-DCs through mTNF-TNFRII interaction, adding the role of mTNF in the induction of immune tolerance to the list of multiple functions of this cytokine.

Indoleamine 2,3-dioxygenase (IDO) and aryl hydrocarbon receptor (AhR) have been implicated as negative regulators of the inflammatory response by modulating the Th1/Th2 balance (Negishi et al., 2005), and regulation of Treg and Th17 cell differentiation (Quintana et al., 2008). We did not find evidence for the contribution of these molecules in modulated DCs.

**PRRs AND RESISTANCE TO MATURATION**

Several synthetic TLR ligands activate DC subsets and promote their adjuvant pro-inflammatory capacity, which can be a useful tool in certain types of vaccines. DC express a broad repertoire of TLRs with 10 members of the family described to date in human (Medzhitov, 2001). TLRs trigger the signals that provide DC maturation and the initiation of adaptive immune responses against pathogens. The most known ligand for TLR4 is LPS (Medzhitov, 2001), whereas TLR2 discriminates lipoproteins from Gram-positive bacteria in association with TLR1 or TLR6 (Schwandner et al., 1999; Takeuchi et al., 2002). In addition, self-proteins can be recognized by both TLR2 and TLR4 (Asca et al., 2002).

The TLR repertoire on tolerogenic DCs modulated in vitro with IL-10, dexamethasone, or Vitamin D appears similar to that of immunogenic DCs, although with slight differences in the expression levels of TLR2 and TLR4 (Chamorro et al., 2009). However, tolerogenic DCs responded differently to TLR-mediated signals than immunogenic DCs showing partial maturation with low to intermediate levels of CD80, CD86, and CCR7, reduced ability to stimulate allogeneic T cells and secretion of the suppressive cytokine IL-10 combined with very low production of IL-12 or the related cytokines IL-23 and IL-27. The finding that partially matured DCs respond to TLR2 stimulation with an anti-inflammatory program could shed light on why patients with severe sepsis undergo long-term systemic and local immunosuppression despite their increased TLR2 expression (Armstrong et al., 2004), and how TLR2-derived signals from *Candida albicans* or *Schistosoma* infections drive immunosuppression by IL-10 production and Treg induction (van der Kleij et al., 2002; Netea et al., 2004). Indeed, TLR2 participates in the induction of peripheral tolerance (Dillon et al., 2006), in the promotion of T regulatory responses leading to protection against autoimmune diseases in vivo (Manicassamy et al., 2009). Thus, the TLR2 up-regulation and activation on VD3- and Dex-treated DCs might enhance their tolerogenic properties.

In vivo application of DCs in patients faces possible pro-inflammatory triggering and the tolerogenic DC vaccine should not divert into pro-inflammatory DC upon injection. Preservation of tolerogenic function in the settings of an activated immune system (resistance to maturation) is therefore considered a prerequisite of tolerogenic potential for immunomodulatory vaccines.

Pro-inflammatory DC maturation is induced when DCs sense microbes through PRRs, interact with T cells (through CD40) or get exposed to inflammatory cytokines. We mimicked *in vivo* DC activation by re-stimulating matured tolerogenic DCs with LPS, CD40-L, or the cocktail of cytokines (IL-6, TNF, IL-1β, and PGE2), and demonstrated that DCs modulated with Vitamin D alone or combined with dexamethasone maintained a stable regulatory phenotype, IL-10 production, and low stimulation of allogeneic T cells upon repeated maturation with either LPS, CD40-L, or cytokine mix. Similarly, a study comparing resistance to re-stimulation with LPS of the rapamycin-, dexamethasone-, and Vitamin D-treated DCs, demonstrated a stable high IL-10 and no IL-12/IL-23 production (Naranjo-Gomez et al., 2011).

**MODULATED DC ARE EQUIPPED TO MIGRATE TO INFLamed AND SECONDARY LYMPHoid TISSUES – CHEMOKINE PRODUCTION UPON TLR TRIGGERING**

To be effective in silencing reactive T cells or inducing tissue-specific Tregs in vivo, it is of key importance that injected modulated DCs reach lymphoid tissues or the inflamed site. We therefore examined the expression of several chemokine receptors. Immature Dex-, VD3-, and moDCs expressed significant levels of CCR4 and CCR5, but no CCR7 (Unger et al., 2009). Upon maturation, CCR4 and CCR5 were down-regulated, whereas CCR7 was up-regulated by all DCs indicating the ability to migrate to secondary lymphoid tissues. CXCR3 was expressed on the surface of the modulated DCs, which may guide these cells to the inflammatory lesion in the pancreas to counteract autoreactive T cells around the distressed islets (van Halteren et al., 2005; Roep et al., 2010).

**PREVENTING PRIMING OF NAÏVE T CELLS – NEGLecTION OR ACTIVE INHIBITION?**

Schematic representation of molecules involved in the tolerogenic function of VD3-modulated DCs is given in Figure 2. VD3-DC and Combi-DC impair priming of naïve CD4 and CD8 T cells (Unger et al., 2009; Kleijwegt et al., 2013). Naïve T cells require antigen recognition, co-stimulation, and activating cytokines (mostly IL-12) to become effector T cells. VD3-DC and Combi-DCs express lower levels of co-stimulatory molecules and IL-12, providing incomplete stimulation to T cells. However, our data show that besides hampered stimulation, an active repression prevents priming of naïve T cells (Kleijwegt et al., 2013). Combi-DCs produce TNF and TGF-β (Chamorro et al., 2009; Kleijwegt et al., 2010), but neither of these cytokines contributed to the obstructed priming of CD8 T cells. Since Combi-DCs interfere with priming only when they present the cognate antigen to the T cell, mechanisms related to TCR signaling may be responsible for this effect. This could happen through failing trans-presentation of IL-15, IL-2 (Combi-DCs lack CD25 expression), or high ILT-3 expression, as demonstrated in other systems (Chamorro et al., 2009; Frasca et al., 2010; Kleijwegt et al., 2010; Huntington et al., 2011).

**KILLING OF T CELLS BY TOLEROGEnIC DCs – THE STORY OF MR. AND MS. SMITH**

Tolerogenic mechanisms of VD3-DCs include deletion of naïve T cells since the cell numbers after the co-culture with VD3-DCs are reduced compared to the cultures with non-treated moDCs. The
Nikolic and Roep

FIGURE 2 | Molecules involved in the tolerogenic function of Vitamin D-modulated DCs (VD3-DCs). VD3-DC express MHC class II in combination with low co-stimulatory molecules (CD80/86) and high expression of PD-L1, which enable antigen-dependent elimination of Th1 effector T cells and induction of antigen-specific adaptive regulatory T cells (iTregs). VD3-DCs express additional regulatory molecules: TLR2, ILT-3, and membrane-bound TNF (mTNF), and produce IL-10, which potentiate the tolerogenic function of VD3-DCs. VD3-DCs also express chemokines, which enable the migration both to lymph nodes (CCR7) and to the site of inflammation (CXCR3).

The finding that tolerogenic DCs induce elimination of effector CD8 T cells initially appeared to offer a valuable tool to tackle the ability of DCs to kill target cells that could serve in anti-tumor immunity or T-cell killing in autoimmunity and transplantation has been described (Chauvin and Josien, 2008). A recent study in pulmonary tuberculosis patients confirms the cytotoxic activity of DCs as a mechanism of negative regulation of T lymphocytes (Sakhno et al., 2012). In case of VD3-DCs, this action is antigen-dependent but not restricted to naïve T cells since VD3-DCs also block IFNγ and IL-10 production and induce active killing of a diabetogenic Th1 clone in an antigen-specific manner (van Halteren et al., 2002). When interacting with memory CD8 T cells, Combi-DCs initially expand this cell pool, which collapses after the subsequent re-stimulation (Kleijwegt et al., 2013). This is caused by an increased cell death in the second co-culture. To test whether memory CD8 T cells undergo increased apoptosis in the second culture due to the primary interaction with tolerogenic DCs, memory CD8 T cells initially stimulated with tolerogenic DCs were subsequently re-stimulated with moDCs. This only partially rescued CD8 T cells from the collapse in the second culture, implying that during the first stimulation tolerogenic DCs endorse memory CD8 T cells with features underlying their subsequent ceased growth. The depletion of CD8 T cells by Combi-DCs could result from a combined action of the withdrawal of positive signals (co-stimulation and cytokines) and inhibition by secreted regulatory factors (such as IL-10 and TGF-β), creating a less favorable environment for cytotoxic T cell survival and expansion (Bots et al., 2007; Toda et al., 2011). This process could also involve expression of CXCR3 facilitating memory degeneration, inhibition of autocrine IL-2 production, or induction of pro-apoptotic signals as described in other models (Kurachi et al., 2011; Takata et al., 2012).

The finding that tolerogenic DCs induce elimination of effector CD8 T cells initially appeared to offer a valuable tool to tackle the...
destructive forces such as autoreactive CD8 T cells in the pancreas of patients with type 1 diabetes by loading diabetogenic MHC-class I peptides onto tolerogenic DCs. However, a draw-back in this respect was our finding that antigen-loaded tolerogenic DCs were eliminated by the cytotoxic CD8 T cells through a Granzyme B-dependent mechanism (Kleijwegt et al., 2013). DCs have the ability to protect themselves from being killed using protective molecules like Serpin 9 or Cathepsin B (Bots et al., 2007) or by up-regulation of antiapoptotic proteins, such as Bcl-xL (Gutierrez et al., 2007). Indeed, tolerogenic DCs were more protected from killing than moDCs or B cells. Yet, in order to preserve the immunomodulatory action of tolerogenic vaccine on other cell types, loading of MHC-class I epitopes does not appear to add to MHC-class II epitopes on tolerogenic DCs.

**VITAMIN D3-TREATED DCs INDUCE INFECTIOUS TOLERANCE THROUGH ANTIGEN-SPECIFIC TREGS**

As established above, VD3- and Combi-DCs induce Tregs that suppress in an antigen-dependent manner, which is specialized feature of 1,25(OH)2D3-treated DCs. Rapa-DC-primed T cells exhibit reduced alloproliferation along with a concomitant expansion of naturally occurring iTregs (Kang et al., 2008; Simonetta et al., 2010), and Dex-DCs induce adaptive Tregs that suppress in an antigen-independent fashion (Unger et al., 2009). PD-L1 and mTNF play important roles in the mechanisms by which VD3-DCs induce allo-reactive or proinsulin specific Tregs (Kleijwegt et al., 2011).

Induced (adaptive) proinsulin-peptide specific Tregs (iTregs) suppress diabetogenic Th1 cells via linked suppression and do not need IL-10 or TGF-β to perform their suppressive functions (Kleijwegt et al., 2011). Tregs may exert their antigen-specific function via cytolysis of the APCs, metabolic disruption, or by modulating the immunogenic function of DCs (Vignali et al., 2008). We have demonstrated that iTregs induced by VD3-DC perform two of three described functions and the contribution of iTregs to metabolic disruption remains to be investigated. iTregs re-educate pro-inflammatory moDCs in an antigen-specific manner by changing the phenotype (@DC), which differs from VD3-DCs used to generate iTregs: VD3-DCs have low CD80 and CD86, high ILT-3 and PD-L1, low ICOSL, and no B7-H3 expression (Unger et al., 2009), whereas @DCs retain high expression of HLA-DR and co-stimulatory molecules CD80 and CD86, and low expression of inhibitory molecules PD-L1, ILT-3, and ILT-4 (Kleijwegt et al., 2011). The difference in phenotype may originate in the mode of modulation: VD3-DCs result from modulation of monocytes with vitamin D3 during differentiation, whereas iTregs alter fully differentiated mature moDCs into @DC. The specific alteration of antigen-bearing moDCs, which persisted upon removal of iTregs, was characterized by up-regulation of B7-H3 and ICOSL. Both molecules are involved in immune regulation: B7-H3 preferentially dampens Th1-mediated responses (Suh et al., 2003), whereas ICOSL promotes IL-10 secretion by T cells (Witsch et al., 2002) and induces Tr1 cells that produce IL-10 and inhibit experimental airway inflammation in mice (Akbari et al., 2002; Conrad et al., 2012). The induction of IL-10–producing T cells by human @DCs was indeed mediated through ICOSL.

Infectious tolerance is a process in which a tolerance-inducing state is transferred from one cell population to another and is supported by different mechanisms, including IL-35, TGF-β production, or essential amino acid-depleting enzymes (Jonuleit et al., 2002; Cobbold et al., 2009; Collison et al., 2010). VD3-DCs transfer tolerogenic properties to mature pro-inflammatory DC via iTregs, which operate in an antigen-dependent manner (modeled in Figure 3). When applied as an intervention therapy, this implies that Tregs specific for a single auto antigen...
generated by tolerogenic DCs could alter other local DCs that subsequently reduce autoimmune responses to a diverse range of tissue-associated antigens.

Interplay between DCs and Tregs is essential for the immune tolerance since a direct correlation between DC numbers and Treg cells has been found as part of a feedback-control mechanism (Darrasse-Jeze et al., 2009). DCs promote and enhance the suppression by Treg cells and in turn, Tregs condition other DCs to upregulate inhibitory molecules and modulate effector responses. Instillation of VD3-DCs in this loop would support the regulatory and anti-inflammatory forces in the setting of autoimmune response that has escaped the regular control.

CONCLUDING REMARKS – TOWARD A TOLERGENIC IMMUNOTHERAPY WITH DCs

Getting hold of a method to obtain efficient tolerogenic DCs in the clinical setting is a holy grail that will enable reshaping the immune response to particular needs. This may be accomplished using ex vivo modulated DCs. These cells might not be the same as tolerogenic DCs that exist in vivo and might need to be repetitively injected to achieve a continuous tolerogenic treatment. However, the ex vivo generation of tolerogenic DCs permits the propagation of sufficient amounts of cells in controlled conditions and loading with an antigen of choice thereby enabling targeted tolerizing immunotherapies.

Tolerogenic DCs modulated using the biologically active form of vitamin D (1,25(OH)2D3) are a promising tool for tolerance induction in clinic. Years of investigation of these tolerogenic DCs have helped understand the contribution of different PRRs and secondary signals in facilitating tolerogenic DCs to prime antigen- and tissue-specific Tregs by mechanisms such as linked suppression and infectious tolerance. These learned lessons helped understanding how a cross-talk between DCs and T cells translates into immune regulation and may support finding therapies with small molecules that recapitulate the mode of action of cell therapy.

REFERENCES

Adorini, L., Penna, G., Giarratana, N., and Uskokovic, M. (2003). Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases. J. Cell. Biochem. 88, 227–233.

Akbari, O., Freeman, G. J., Meyer, E. H., Greenfield, E. A., Chang, T. T., Sharpe, A. H., et al. (2002). Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat. Med. 8, 1024–1032.

Amsen, D., Blander, J. M., Lee, G. R., Tanigaki, K., Honjo, T., and Flavell, R. A. (2004). Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells. Cell 117, 515–526.

Armstrong, L., Medford, A. R., Hunter, K. J., Uppington, K. M., and Mil lar, A. B. (2004). Differential expression of Toll-like receptor (TLR)-2 and TLR-4 on monocytes in human sepsis. Clin. Exp. Immunol. 136, 312–319.

Asea, A., Rehli, M., Kabinbu, E., Boch, J. A., Bare, O., Auron, P. E., et al. (2002). Novel signal transduction pathway utilized by extracellu lar HSPI70: role of toll-like receptor (TLR) 2 and TLR4. J. Biol. Chem. 277, 15028–15034.

Atifat, C., Sieveke, M. H., and Geissmann, F. (2009). Blood monoocytes: development, heterogeneity, and relationship with dendritic cells. Annu. Rev. Immunol. 27, 669–692.

Barke, F., Korf, H., Overhleg, L., Verstuyf, A., Thorrez, L., Van, L. L., et al. (2011). The vitamin D analog, TX527, promotes a human CD4(+/CD23high)/CD127low regulatory T cell profile and induces a migratory signature specific for homing to sites of inflammation. J. Immunol. 186, 132–142.

Birnberg, T., Bar-On, L., Sapoznikov, A., Caton, M. L., Cervantes-Barragan, L., Makia, D., et al. (2008). Lack of conventional dendritic cells is compatible with normal development and T cell homeostasis, but causes myeloid proliferative syndrome. Immunity 29, 986–997.

Black, R. A., Rauch, C. T., Koslosky, J. C., Peschon, J. J., Slack, J. L., Wolfson, M. F., et al. (1997). A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385, 729–733.

Bots, M., de, B. E., Rademaker-Koot, M. T., and Medema, J. P. (2007). Proteinase inhibitor-9 expression is induced by maturation in dendritic cells via p38 MAP kinase. Hum. Immunol. 68, 959–964.

Braun, J., Brebah, M., and Maksymowycz, W. P. (2002). Therapy for ankylosing spondylitis: new treatment modalities. Best Pract. Res. Clin. Rheumatol. 16, 631–651.

Buckland, M., and Lombardi, G. (2009). Aspirin and the induction of tolerance by dendritic cells. Haematol. Exp. Pharmacol. 188, 197–213.

Burnmeister, Y., Lischke, T., Dahler, A. C., and Maksymowycz, W. P. (2002). Therapy for ankylosing spondylitis: new treatment modalities. Best Pract. Res. Clin. Rheumatol. 16, 631–651.

Campbell, D. I., and Butcher, E. C. (2002). Rapid acquisition of tissue-specific homing phenotypes by CD4(+)(T) cells activated in cuta neous or mucosal lymphoid tissues. J. Exp. Med. 195, 135–141.

Chamorro, S., Garcia-Vallejo, J. J., Unger, W. W., Fernandes, R. J., Bruij ns, S. C., Laban, S., et al. (2009). TRL triggering on tolerogenic dendritic cells results in TRL2 up-regulation and a reduced proinflammatory immune program. J. Immunol. 183, 2984–2994.

Chauvin, C., and Josien, R. (2008). Dendritic cells as killers: mechanistic aspects and potential roles. J. Immunol. 181, 11–16.

China, W. K., Wang, W. W., Teo, M., Tai, W. M., Lim, W. T., Tan, E. H., et al. (2012). A phase II study evaluating the safety and efficacy of an adenovirus-DeltaLMP1-LMP3 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma. Ann. Oncol. 23, 997–1005.

Chu, C. C., Ali, N., Karagiannis, P., Di, M. P., Skowera, A., Napolitano, L., et al. (2012). Resident CD141(BDCA3) dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation. J. Exp. Med. 209, 935–945.

Collisson, L. W., Chatuvredi, V., Henderson, A. L., Giaconia, P. R., Goy, C., Bankoti, J., et al. (2010). IL-35-mediated induction of a potent regulatory T cell population. Nat. Immunol. 11, 1093–1101.

Conrad, G., Gregorio, I., Wang, Y. H., Ito, T., Meller, S., Hanabuchi, S., et al. (2012). Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T regulatory cells. Cancer Res. 72, 5240–5249.

Coquerelle, C., and Moser, M. D. C. (2010). Subsets in positive and negative regulation of immunity. Immunol. Rev. 234, 317–334.

Crozet, K., Tamoutounour, S., Vu Manh, T. P., Fossom, E., Luche, H., Ardoin, L., et al. (2011). Cutting edge: expression of XCR1 defines mouse lymphoid–tissue resident and migratory dendritic cells of the CD8alpha(+) type. J. Immunol. 187, 4411–4415.

Darrasse-Jeze, G., Derouaux, S., Mouquet, H., Victora, G. D., Eisenreich, T., Yao, K. H., et al. (2009). Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. J. Exp. Med. 206, 1853–1862.

de la Fuente, H., Cibrian, D., and Sanchez-Madrid, F. (2012). Immunoregulatory molecules are master regulators of inflammation during the immune response. FEBS Lett. 586, 2897–2905.

Dillon, S., Agrawal, S., Banerjee, K., Letterio, J., Denning, T. L., Oswald-Richter, K., et al. (2006). Yeast zymosan, a stimulus forTLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance. J. Clin. Invest. 116, 916–928.
Dominguez, P. M., and Ardavin, C. (2010). Differentiation and function of mouse monocyte-derived dendritic cells in steady state and inflammation. *Immunol. Rev.* 234, 90–104.

Downing, I., Macdonald, S. L., Atkinson, A. P., Turner, M. L., and Kilpatrick, D. C. (2012). Drug modification of LPS-stimulated human monocyte-derived dendritic cells. *Br. J. Biomed. Sci.* 69, 126–133.

Drakes, M. L., Stiff, P. J., and Blanchard, T. G. (2009). Inverse relationship between dendritic cell CCR9 expression and maturation state. *Immunology* 127, 466–476.

Feldmann, M., and Maini, R. N. (2003). Lasker clinical medical research award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. *Nat. Med.* 9, 1245–1250.

Ferreira, G. B., Kleijwegt, F. S., Waelkens, J. M. P., van E., E. E., Lage, K., Nikolic, T., Hansen, D. A., et al. (2012). Differential protein pathways in 1,25-dihydroxyvitamin D3 and dexamethasone modulated tolerogenic human dendritic cells. *J. Proteome Res.* 11, 941–971.

Ferreira, G. B., van, E. E., Lage, K., Hansen, D. A., Moreau, Y., Workman, C. T., et al. (2009). Proteome analysis demonstrates profound alterations in human dendritic cell nature by TXS77, an analogue of vitamin D. *Proteomics* 9, 3752–3764.

Germain, R. N. (2010). Vaccines and Frasca, L., Stonier, S. W., Overwijk, W. W., and Reizis, B. (2012). Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? *Trends Immunol.* 23, 445–449.

Gomez, M. G., Satmuller, R., Hermann, C., Van der Graaf, C. A., Van der Meer, J. W., van Kriekien, J. H., et al. (2004). Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells. *J. Immunol.* 172, 3714–3721.

Görecki, D. P., Wrzesień, M., Rudek, A. M., Toutouza, M., Peñalva, O. L., Hoogerbrugge, F. H., et al. (2011). Unique myeloid DC subset with the capacity to present necrotic cell antigens. *J. Exp. Med.* 207, 2461–2470.

Hofman, M. A., Netea, M. G., and Kullberg, B. J. (2010). The interferon pathway in human dendritic cells. *Blood* 115, 754–761.

Huang, X., Kong, J., and Blumenthal, D. (2006). T cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. *Immunol. Today* 20, 561–567.

Jang, J., Huddlestone, S. J., Fraser, J. M., and Kherunts, A. (2008). De novo induction of antigen-specific CD4+CD25+Foxp3+ regulatory T cells in vivo following systemic anti-gen administration accompanied by blockade of mTOR. *J. Leukoc. Biol.* 83, 1230–1239.

Kel, J. M., Girard-Madoux, M. J., Reizis, B., and Clausen, B. E. (2010). TFG beta is required to maintain the pool of immature Langerhans cells in the epidermis. *J. Immunol.* 185, 3248–3255.

Kidd, P. (2003). TH1/TH2 balance: the hypothesis, its limitations, and implications for health and disease. *Altern. Med. Rev.* 8, 223–246.

King, L. J., Kroecken, M. A., and Segal, B. M. (2010). GM-CSF-dependent, CD103+ dermal dendritic cells play a critical role in Th effector cell differentiation after subcutaneous immunization. *J. Exp. Med.* 207, 953–961.

Kleijwegt, F. S., Hansen, D. A., Workman, C. T., et al. (2009). An anti-inflammatory role for TNF in the induction of human antigen-specific regulatory T cells by dendritic cells. *Immunol. Rev.* 247, 515–548.

Kleijwegt, F. S., van, E. E., Lage, K., Nikolic, T., Hansen, D. A., et al. (2012). Differentiation and function of mouse monocyte-derived dendritic cell behaviour in vitro and in vivo. *Diabetes Metab. Res. Rev.* 28, 680–6805.

Kovacs, G., Nikolic and Roep Regulatory multitasking of tolerogenic DCs.
and Versnel, M. A. (2009). Plasmacytoid dendritic cells in autoimmune diabetes – potential tools for immunotherapy. *Immunobiology* 214, 791–799.

Ohnacht, C., Pullner, A., King, S. B., Drexler, I., Meier, S., Brocker, T., et al. (2009). Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity. *J. Exp. Med.* 206, 549–559.

Palucka, A. K., Dhoopar, M. V., Paczynski, S., Burkholler, S., Witkowski, K. M., Steinman, R. M., et al. (2003). Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma. *J. Immunother.* 26, 432–438.

Palucka, K., and Banchereau, J. (2012). Cancer immunotherapy via dendritic cells. *Nat. Rev. Cancer* 12, 265–277.

Pasare, C., and Medzhitov, R. (2003). Toll-pathway-dependent blockade of CD4+CD25+ T-cell-mediated suppression by dendritic cells. *Science* 299, 1033–1036.

Pedersen, A. E., Schmidt, E. G., Gad, M., Poulsen, S. S., and Claesson, M. H. (2009). Dexamethasone/1alpha,25-dihydroxyvitamin D3-treated dendritic cells suppress colitis in the SCID T-cell transfer model. *Immunology* 127, 118–128.

Penn, G., Amuchastegui, S., Giarratana, N., Daniel, K. C., Vulcano, M., Sozzani, S., and Germain, R. N. (2007). 1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. *J. Immunol.* 178, 145–153.

Piermonti, L., Monti, P., Allavena, P., Sironi, M., Soldini, L., Leone, B. E., et al. (2007). Cytotoxic cytokines affect human dendritic cell differentiation and maturation. *J. Immunol.* 162, 6473–6481.

Piermonti, L., Monti, P., Sironi, M., Fratìci, P., Leone, B. E., Dal, C. E., et al. (2000). Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. *J. Immunol.* 164, 4443–4451.

Poulin, L. F., Salio, M., Griessinger, E., Anjos-Afonso, F., Craciun, L., Chen, J. L., et al. (2010). Characterization of human DNGR-1-like receptors as putative equivalents of mouse CD168α and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. *J. Biol. Chem.* 274, 17406–17409.

Simoñetta, F., Chiali, A., Cordier, C., Urrutia, A., Girault, I., Bloquet, S., et al. (2010). Increased CD127 expression on activated FOXP3+CD4+ regulatory T cells. *Eur. J. Immunol.* 40, 2528–2538.

Singh, V. K., Mehrotra, S., and Agarwal, S. S. (1999). The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy. *Immunol. Res.* 20, 147–161.

Steinbrink, K., Wollf, M., Jonuleit, H., Knop, J., and Enk, A. H. (1997). Induction of tolerance by IL-10-treated dendritic cells. *J. Immunol.* 159, 4772–4781.

Steinman, R. M., Hawiger, D., and Nussenzweig, M. C. (2003a). Tolerogenic dendritic cells. *Annu. Rev. Immunol.* 21, 685–711.

Steinman, R. M., Hawiger, D., Liu, K., Bonifaz, L., Bonnyay, D., Mahnke, K., et al. (2003b). Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. *Ann. N. Y. Acad. Sci.* 987, 15–25.

Suh, W. K., Gajeiwka, B. S., Okada, H., Gronski, M. A., Bertram, E. M., Dowick, W., et al. (2003). The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. *Nat. Immunol.* 4, 899–906.

Swiecki, M., and Colonna, M. (2010). Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. *Immunol. Rev.* 234, 142–162.

Tack, C. J., Kleijwegt, F. S., Van Riel, P. L., and Roep, B. O. (2009). Development of type 1 diabetes in a patient treated with anti-TNF-alpha therapy for active rheumatoid arthritis. *Diabetologia* 52, 1442–1444.

Takeuchi, H., Fukaya, T., Eizumi, K., Sato, Y., Sato, K., Shihabazaki, A., et al. (2011). Plasmacytoid dendritic cells are crucial for the initiation of inflammation and T cell immunity in vivo. *Immunity* 35, 958–971.

Takahata, N., Naruto, T., and Takiguchi, M. (2012). Functional heterogeneity of human effecter CD8+ T cells. *Blood* 119, 1390–1398.

Takeuchi, O., Sato, S., Hirosue, T., Hoshino, K., Takatsuki, K., Dong, Z., et al. (2002). Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipopolysaccharides. *J. Immunol.* 169, 10–14.

Toda, M., Wang, L., Ogura, S., Torii, M., Kurachi, M., Kakim, K., et al. (2011). UV irradiation of immunized mice induces type 1 regulatory T cells that suppress tumor antigen specific cytotoxic T lymphocyte responses. *Int. J. Cancer* 129, 1126–1136.

Unger, W. W., Laban, S., Kleijwegt, F. S., van der Sliek, A. R., and Roep, B. O. (2009). Induction of Treg by monocytic-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1. *Eur. J. Immunol.* 39, 3147–3159.

Valencia, J., Hernandez-Lopez, C., Martinez, V. G., Hidalgo, L., Zapata, A. G., Vicente, A., et al. (2011). Wnt5a skews dendritic cell differentiation to an unconventional phenotype with tolerogenic features. *J. Immunol.* 187, 4129–4139.

van der Kleij, D., Lutz, E., Browers, J. F., Kruize, Y. C., Schmitz, M., Kurt-Jones, E. A., et al. (2002). A novel host-parasite lipid cross-talk. *Schistosomiasis and helminth infections* activate toll-like receptor 2 and affects immune polarization. *J. Biol. Chem.* 277, 48122–48129.

van Halteren, A. G., Kardol, M. J., Mulder, A., and Roep, B. O. (2005). Homing of human autoreactive T cells into pancreatic tissue of NOD-scid mice. *Diabetologia* 48, 75–82.

van Halteren, A. G., Tysma, O. M., van, E. E., Mathieu, C., and Roep, B. O. (2004). Alpaha25-dihydroxyvitamin D3 or analogue treated dendritic cells modulate human autoreactive T cells via the selective induction of apoptosis. *J. Autoimmun.* 23, 233–239.

van Halteren, A. G., van, E. E., de Jong, E. C., Bouillon, R., Roep, B. O., and Mathieu, C. (2002). Redirection of human autoreactive T-cells upon interaction with dendritic cells modulated by TX527, an analog of 1.25-dihydroxyvitamin D(3). *Diabetes* 51, 2119–2125.

Vendetti, S., Chai, J. G., Dyson, J., Simpson, E., Lombardi, G., and Lechler, R. (2000). Anergic T cells inhibit the antigen-presenting function of dendritic cells. *J. Immunol.* 165, 1175–1181.

Vignali, D. A., Collison, L. W., and Workman, C. J. (2008). How regulatory T cells work. *Nat. Rev. Immunol.* 8, 51–62.
imprinting. *Histol. Histopathol.* 23, 897–910.

Witsch, E. J., Peiser, M., Hudloff, A., Buschner, K., Dorner, B. G., Jonuleit, H., et al. (2002). ICOS and CD28 reversely regulate IL-10 on re-activation of human effector T cells with mature dendritic cells. *Eur. J. Immunol.* 32, 2680–2686.

Wuest, S. C., Edwan, J. H., Martin, J. E., Han, S., Perry, J. S., Cartagenia, C. M., et al. (2011). A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. *Nat. Med.* 17, 604–609.

Yamazaki, S., Dudziak, D., Heidkamp, G. F., Fiorese, C., Bonito, A. J., Inaba, K., et al. (2008). CD+CD205+ splenic dendritic cells are specialized to induce Foxp3+ regulatory T cells. *J. Immunol.* 181, 6923–6933.

Yoge, N., Frommer, F., Lukas, D., Kautz-Neu, K., Karaz, K., Ielo, D., et al. (2012). Dendritic cells ameliorate autoimmunity in the CNS by controlling the homeostasis of PD-1 receptor(+) regulatory T cells. *Immunity* 37, 264–275.

Zimmer, A., Bouley, J., Le, M. M., Pliquet, E., Horiot, S., Turfkruyer, M., et al. (2012). A regulatory dendritic cell signature correlates with the clinical efficacy of allergen-specific sublingual immunotherapy. *J. Allergy Clin. Immunol.* 129, 1020–1030.

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 11 January 2013; paper pending published: 09 February 2013; accepted: 29 April 2013; published online: 14 May 2013.

Citation: Nikolic T and Roep BO (2013) Regulatory multitasking of tolerogenic dendritic cells – lessons taken from vitamin D3-treated tolerogenic dendritic cells. *Front. Immunol.* 4:113. doi: 10.3389/fimmu.2013.00113

This article was submitted to Frontiers in Antigen Presenting Cell Biology, a specialty of Frontiers in Immunology. Copyright © 2013 Nikolic and Roep. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.